{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:22:18Z","timestamp":1791487338213,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In January 2018, the Government of Ontario, Canada, initiated a universal pharmacare program (OHIP+) for all individuals aged 24 years and younger. In April 2019, the program was amended to cover only children and youth without private insurance. Because benzodiazepines are commonly prescribed to children and youth despite their potential hazards, we examined whether changes in publicly-funded drug coverage influenced benzodiazepine dispensing trends in this demographic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a population-based natural experiment study of benzodiazepine dispensing to children and youth in Ontario between January 2013 and March 2020. We used interventional autoregressive integrated moving average models to estimate the impact of OHIP\u2009+\u2009and its subsequent modification on these trends.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The implementation of OHIP\u2009+\u2009was associated with an immediate increase in the monthly rate of benzodiazepine dispensing of 12.9 individuals per 100,000 population (95% confidence interval [CI]; 7.5 to 18.3 per 100,000). Benzodiazepine dispensing rates rose from 214.2 to 241.5 per 100,000 from December 2017 to March 2019, a 12.8% (95% CI 9.6\u201316.0%) increase. In stratified analyses, increases were most pronounced among females, children and youth living in the lowest income neighbourhoods and individuals aged 20 to 24. The April 2019 modification to OHIP\u2009+\u2009was not associated with changes in monthly benzodiazepine dispensing trends (0.39 individuals per 100,000; 95% CI -1.3 to 2.1 per 100,000). However, rates remained elevated relative to the period preceding OHIP\u2009+\u2009implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Implementation of a publicly-funded pharmacare program resulted in more children and youth being prescribed benzodiazepines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-023-04331-4","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:02:39Z","timestamp":1697688159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of a publicly-funded pharmacare program policy on benzodiazepine dispensing among children and youth: a population-based natural experiment"],"prefix":"10.1186","volume":"23","author":[{"given":"Tony","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Lunsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"4331_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00228-019-02711-3","volume":"75","author":"D Piovani","year":"2019","unstructured":"Piovani D, Clavenna A, Bonati M. Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data. Eur J Clin Pharmacol. 2019;75:1333\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"4331_CR2","doi-asserted-by":"publisher","first-page":"e007070","DOI":"10.1136\/bmjopen-2014-007070","volume":"5","author":"K O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan K, Reulbach U, Boland F, Motterlini N, Kelly D, Bennett K, et al. Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland. BMJ Open. 2015;5:e007070.","journal-title":"BMJ Open"},{"key":"4331_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/pds.4123","volume":"26","author":"A B\u00e9nard-Laribi\u00e8re","year":"2017","unstructured":"B\u00e9nard-Laribi\u00e8re A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, et al. Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study. Pharmacoepidemiol Drug Saf. 2017;26:162\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4331_CR4","doi-asserted-by":"publisher","first-page":"e1002635","DOI":"10.1371\/journal.pmed.1002635","volume":"15","author":"A Sidorchuk","year":"2018","unstructured":"Sidorchuk A, Isomura K, Molero Y, Hellner C, Lichtenstein P, Chang Z, Franck J, de la Fern\u00e1ndez L, Mataix-Cols D. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study. PLoS Med. 2018;15:e1002635.","journal-title":"PLoS Med"},{"key":"4331_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00228-004-0765-9","volume":"60","author":"JG Hugtenburg","year":"2004","unstructured":"Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995\u20132001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60:377\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"4331_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.3825","volume":"25","author":"C Huerta","year":"2016","unstructured":"Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven european electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):56\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4331_CR7","doi-asserted-by":"publisher","first-page":"E208","DOI":"10.9778\/cmajo.20130076","volume":"2","author":"S Alessi-Severini","year":"2014","unstructured":"Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open. 2014;2:E208\u201316.","journal-title":"CMAJ Open"},{"key":"4331_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bcpt.12706","volume":"120","author":"ES Nielsen","year":"2017","unstructured":"Nielsen ES, Rasmussen L, Hellfritzsch M, Thomsen PH, N\u00f8rgaard M, Laursen T. Trends in off-label prescribing of sedatives, hypnotics and antidepressants among children and adolescents - a danish, Nationwide Register-Based study. Basic Clin Pharmacol Toxicol. 2017;120:360\u20137.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4331_CR9","doi-asserted-by":"publisher","unstructured":"Campbell TJ, Men S, Shearer D, Ebejer T, Joosse M, Quercia J et al. The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study. Can J Public Health 2023 Jun 15:1\u201311. https:\/\/doi.org\/10.17269\/s41997-023-00784-3. Epub ahead of print.","DOI":"10.17269\/s41997-023-00784-3"},{"key":"4331_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/tp.2017.08.05","volume":"7","author":"DR Patel","year":"2018","unstructured":"Patel DR, Feucht C, Brown K, Ramsay J. Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners. Transl Pediatr. 2018;7:23\u201335.","journal-title":"Transl Pediatr"},{"key":"4331_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11126-005-2982-5","volume":"76","author":"MW Witek","year":"2005","unstructured":"Witek MW, Rojas V, Alonso C, Minami H, Silva RR. Review of benzodiazepine use in children and adolescents. Psychiatr Q. 2005;76:283\u201396.","journal-title":"Psychiatr Q"},{"key":"4331_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaac.2020.05.005","volume":"59","author":"HJ Walter","year":"2020","unstructured":"Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, et al. Clinical practice Guideline for the Assessment and treatment of children and adolescents with anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020;59:1107\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"4331_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):1. https:\/\/doi.org\/10.1186\/1471-244X-14-S1-S1.","journal-title":"BMC Psychiatry"},{"key":"4331_CR14","doi-asserted-by":"publisher","first-page":"16m11415","DOI":"10.4088\/JCP.16m11415","volume":"79","author":"GA Bushnell","year":"2018","unstructured":"Bushnell GA, Compton SN, Dusetzina SB, Gaynes BN, Brookhart MA, Walkup JT, et al. Treating Pediatric anxiety: initial use of SSRIs and other Antianxiety prescription medications. J Clin Psychiatry. 2018;79:16m11415.","journal-title":"J Clin Psychiatry"},{"key":"4331_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JCP.0000000000000559","volume":"36","author":"JV Bra\u00fcner","year":"2016","unstructured":"Bra\u00fcner JV, Johansen LM, Roesbjerg T, Pagsberg AK. Off-label prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry. J Clin Psychopharmacol. 2016;36:500\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"4331_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/cap.2021.0027","volume":"32","author":"M Smogur","year":"2022","unstructured":"Smogur M, Onesanu A, Plessen KJ, Eap CB, Ansermot N. Psychotropic drug prescription in children and adolescents: approved Medications in European Countries and the United States. J Child Adolesc Psychopharmacol. 2022;32:80\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"4331_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.addbeh.2014.01.009","volume":"39","author":"SE McCabe","year":"2014","unstructured":"McCabe SE, West BT. Medical and nonmedical use of prescription benzodiazepine anxiolytics among U.S. high school seniors. Addict Behav. 2014;39:959\u201364.","journal-title":"Addict Behav"},{"key":"4331_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1037\/adb0000026","volume":"29","author":"CJ Boyd","year":"2015","unstructured":"Boyd CJ, Austic E, Epstein-Ngo Q, Veliz PT, McCabe SE. A prospective study of adolescents\u2019 nonmedical use of anxiolytic and sleep medication. Psychol Addict Behav. 2015;29:184\u201391.","journal-title":"Psychol Addict Behav"},{"key":"4331_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"key":"4331_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2190\/8FR4-QYY1-7MYG-2AGJ","volume":"34","author":"D Ross-Degnan","year":"2004","unstructured":"Ross-Degnan D, Simoni-Wastila L, Brown JS, Gao X, Mah C, Cosler LE, et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med. 2004;34:103\u201323.","journal-title":"Int J Psychiatry Med"},{"key":"4331_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/pds.3466","volume":"22","author":"MJ Bijlsma","year":"2013","unstructured":"Bijlsma MJ, Hak E, Bos J, De Jong-van den Berg LT, Janssen F. Assessing the effect of a guideline change on drug use prevalence by including the birth cohort dimension: the case of benzodiazepines. Pharmacoepidemiol Drug Saf. 2013;22:933\u201341.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4331_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archinte.166.5.572","volume":"166","author":"SA Pearson","year":"2006","unstructured":"Pearson SA, Soumerai S, Mah C, Zhang F, Simoni-Wastila L, Salzman C, et al. Racial disparities in access after regulatory surveillance of benzodiazepines. Arch Intern Med. 2006;166:572\u20139.","journal-title":"Arch Intern Med"},{"key":"4331_CR23","unstructured":"Ministry of Health and Long-Term Care. OHIP+: Children and Youth Pharmacare Key Facts for Prescribers. Available at: https:\/\/www.afhto.ca\/wp-content\/uploads\/ohip_prescriber-002.pdf. Accessed October 2, 2022."},{"key":"4331_CR24","unstructured":"Ministry of Health and Long-Term Care. OHIP + Redesign Update \u2013 FAQs for Patients. Available at: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/opdp_eo\/notices\/fq_pat_exec_office_20190311.pdf. Accessed October2, 2022."},{"key":"4331_CR25","unstructured":"Statistics Canada. Focus on Geography Series., 2016 Census. Available at: https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/as-sa\/fogs-spg\/Index-eng.cfm. Accessed October 4, 2022."},{"key":"4331_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ije\/20.3.808","volume":"20","author":"U Helfenstein","year":"1991","unstructured":"Helfenstein U. The use of transfer function models, intervention analysis and related time series methods in epidemiology. Int J Epidemiol. 1991;20:808\u201315.","journal-title":"Int J Epidemiol"},{"key":"4331_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-021-01235-8","volume":"21","author":"AL Schaffer","year":"2021","unstructured":"Schaffer AL, Dobbins TA, Pearson SA. Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Med Res Methodol. 2021;21:58.","journal-title":"BMC Med Res Methodol"},{"key":"4331_CR28","first-page":"427","volume":"74","author":"DA Dickey","year":"1979","unstructured":"Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 1979;74:427\u201331.","journal-title":"J Am Stat Assoc"},{"key":"4331_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/biomet\/65.2.297","volume":"65","author":"GM Ljung","year":"1978","unstructured":"Ljung GM, Box GEP. On a measure of lack of fit in time series models. Biometrika. 1978;65:297\u2013303.","journal-title":"Biometrika"},{"key":"4331_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/sim.2580","volume":"26","author":"PC Austin","year":"2007","unstructured":"Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734\u201353.","journal-title":"Stat Med"},{"key":"4331_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","volume":"27","author":"M Solmi","year":"2022","unstructured":"Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27:281\u201395.","journal-title":"Mol Psychiatry"},{"key":"4331_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0706743716640757","volume":"62","author":"JM Lijster","year":"2017","unstructured":"Lijster JM, Dierckx B, Utens EM, Verhulst FC, Zieldorff C, Dieleman GC, et al. The age of onset of anxiety Disorders. Can J Psychiatry. 2017;62:237\u201346.","journal-title":"Can J Psychiatry"},{"key":"4331_CR33","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","volume":"49","author":"KR Merikangas","year":"2010","unstructured":"Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey replication\u2013adolescent supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4331_CR34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, et al. Benzodiazepines: uses, Dangers, and clinical considerations. Neurol Int. 2021;13:594\u2013607.","journal-title":"Neurol Int"},{"key":"4331_CR35","doi-asserted-by":"publisher","first-page":"e20193478","DOI":"10.1542\/peds.2019-3478","volume":"146","author":"GA Bushnell","year":"2020","unstructured":"Bushnell GA, Gerhard T, Crystal S, Olfson M. Benzodiazepine Treatment and Fracture Risk in Young persons with anxiety Disorders. Pediatrics. 2020;146:e20193478.","journal-title":"Pediatrics"},{"key":"4331_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/jcm7020017","volume":"7","author":"J Guina","year":"2018","unstructured":"Guina J, Merrill B, Benzodiazepines I. Upping the care on Downers: the evidence of risks, benefits and Alternatives. J Clin Med. 2018;7:17.","journal-title":"J Clin Med"},{"key":"4331_CR37","unstructured":"Chen J. Are Benzodiazepines the New Opioids? Yale Medicine Reviews, December 11, 2019. Available at: https:\/\/www.yalemedicine.org\/news\/benzodiazepine-epidemic. Accessed October 5, 2022."},{"key":"4331_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/15563650.2019.1674321","volume":"58","author":"JM Friedrich","year":"2020","unstructured":"Friedrich JM, Sun C, Geng X, Calello DP, Gillam M, Medeiros KL, et al. Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data. Clin Toxicol (Phila). 2020;58:725\u201331.","journal-title":"Clin Toxicol (Phila)"},{"issue":"Suppl 2","key":"4331_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1542\/peds.2019-2056I","volume":"145","author":"S Kansagra","year":"2020","unstructured":"Kansagra S. Sleep Disorders in adolescents. Pediatrics. 2020;145(Suppl 2):204\u2013S209.","journal-title":"Pediatrics"},{"key":"4331_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00431-018-3116-z","volume":"177","author":"D Ophoff","year":"2018","unstructured":"Ophoff D, Slaats MA, Boudewyns A, Glazemakers I, Van Hoorenbeeck K, Verhulst SL. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018;177:641\u20138.","journal-title":"Eur J Pediatr"},{"key":"4331_CR41","first-page":"CD005170","volume":"3","author":"JC Ipser","year":"2009","unstructured":"Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009;3:CD005170.","journal-title":"Cochrane Database Syst Rev"},{"key":"4331_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:307\u201349.","journal-title":"J Clin Sleep Med"},{"key":"4331_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/tmj.2007.0035","volume":"14","author":"KM Myers","year":"2008","unstructured":"Myers KM, Valentine JM, Melzer SM. Child and adolescent telepsychiatry: utilization and satisfaction. Telemed J E Health. 2008;14:131\u20137.","journal-title":"Telemed J E Health"},{"key":"4331_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/09540261.2015.1086322","volume":"27","author":"NE Gloff","year":"2015","unstructured":"Gloff NE, LeNoue SR, Novins DK, Myers K. Telemental health for children and adolescents. Int Rev Psychiatry. 2015;27:513\u201324.","journal-title":"Int Rev Psychiatry"},{"key":"4331_CR45","unstructured":"Children\u2019s Mental Health Ontario. Kids can\u2019t wait: 2020 report on wait lists and wait times for child and youth mental health care in Ontario. Available at: https:\/\/cmho.org\/wp-content\/uploads\/CMHO-Report-WaitTimes-2020.pdf. Accessed October 5, 2022."},{"key":"4331_CR46","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0706743716642416","volume":"61","author":"D Gratzer","year":"2016","unstructured":"Gratzer D, Goldbloom D. Making evidence-based psychotherapy more accessible in Canada. Can J Psychiatry. 2016;61:618\u201323.","journal-title":"Can J Psychiatry"},{"key":"4331_CR47","unstructured":"Mental Health Commission of Canada. Options for improving access to counselling, psychotherapy and psychological services for mental health problems and illnesses. Available at: https:\/\/www.mentalhealthcommission.ca\/wp-content\/uploads\/drupal\/2017-07\/Options_for_improving_access_to_counselling_psychotherapy_and_psychological_services_eng.pdf. Accessed October 5, 2022."},{"key":"4331_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/da.22643","volume":"34","author":"H Kuang","year":"2017","unstructured":"Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: a meta-analysis. Depress Anxiety. 2017;34:888\u201396.","journal-title":"Depress Anxiety"},{"key":"4331_CR49","volume-title":"The mental health of children and youth in Ontario: 2017 scorecard","author":"The Mental Health and Addictions Scorecard and Evaluation Framework Research Team","year":"2017","unstructured":"The Mental Health and Addictions Scorecard and Evaluation Framework Research Team. The mental health of children and youth in Ontario: 2017 scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2017."},{"key":"4331_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/02813432.2015.1117282","volume":"33","author":"I Fride Tvete","year":"2015","unstructured":"Fride Tvete I, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prim Health Care. 2015;33:252\u20139.","journal-title":"Scand J Prim Health Care"},{"key":"4331_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.psychres.2017.01.046","volume":"249","author":"C Sj\u00f6stedt","year":"2017","unstructured":"Sj\u00f6stedt C, Ohlsson H, Li X, Sundquist K. Socio-demographic factors and long-term use of benzodiazepines in patients with depression, anxiety or insomnia. Psychiatry Res. 2017;249:221\u20135.","journal-title":"Psychiatry Res"},{"key":"4331_CR52","doi-asserted-by":"publisher","first-page":"e2019029","DOI":"10.1001\/jamanetworkopen.2020.19029","volume":"3","author":"H Taipale","year":"2020","unstructured":"Taipale H, S\u00e4rkil\u00e4 H, Tanskanen A, Kurko T, Taiminen T, Tiihonen J, et al. Incidence of and characteristics Associated with Long-term Benzodiazepine Use in Finland. JAMA Netw Open. 2020;3:e2019029.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-023-04331-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T22:14:36Z","timestamp":1700432076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-023-04331-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1186\/s12887-023-04331-4","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ICES is an independent, non-profit research institute whose legal status under Ontario\u2019s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. ICES is a prescribed entity under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act. Section\u00a045 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects conducted under Sect.\u00a045, by definition, are exempt from and do not require review by a Research Ethics Board. This is confirmed in a letter from the REB of Sunnybrook Health Sciences Centre, ICES\u2019 Research Ethics Board of Record (See Appendix A). This project was conducted under Sect.\u00a045, and approved by ICES\u2019 Privacy and Compliance Office.All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Melanie Penner has received consulting fees for unrelated work from Addis & Associates\/Roche and from the Government of Nova Scotia. Mina Tadrous has received consulting fees for unrelated work from Green Shield Canada and the Canadian Agency for Drugs and Technologies in Health. Tara Gomes has received funding from the Ontario MOH for unrelated work. Tony Antoniou has no competing interests. Daniel McCormack has no competing interests. Sophie Kitchen has no competing interests. Kathleen Pajer has no competing interests. William Gardner has no competing interests. Muhammad Mamdani has no competing interests. Yona Lunsky has no competing interests. David Juurlink has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"519"}}